Tesamorelin
Targeted Peptide Therapy // IVUSE+

Tesamorelin

Tesamorelin at 5mg/mL. The only FDA-approved growth hormone therapy proven to target the deep fat around your organs, the kind you can't crunch away. 44 amino acids, engineered for precision. Stabilized. Targeted. Take as a standalone, or combine with GLP-1's.

5MG/ML
Visceral Fat Reduction Metabolic Optimization Cognitive Function Liver Fat Clearance
Protocol Options

Clinician-prescribed. Ships from a licensed U.S. pharmacy.

Product in context
Lose the fat that weight loss left behind.
The Mechanism

Visceral Fat. Measured, Imaged, Reduced.

The Appetite System
GLP-1
Regulates hunger through gut hormones
Drives weight loss
Mobilizes subcutaneous fat
Does not target visceral stores
The Storage System
Growth Hormone
Regulates where fat is stored
Mobilizes visceral fat through pulsatile GH release
Declines ~14% per decade after 30
By your 40s, running at half capacity

Visceral adipose tissue wraps your organs. It is metabolically distinct from the subcutaneous fat you can pinch. It secretes inflammatory cytokines, drives insulin resistance, and correlates with cardiovascular risk independently of total body weight. Standard dieting reduces subcutaneous fat more readily than visceral. Tesamorelin stimulates pulsatile GH release that selectively mobilizes visceral fat stores. In Phase III trials, CT scans showed an average 15-18% reduction in visceral adipose tissue at 26 weeks. Body weight did not change. Waist circumference did.

Editorial lifestyle
Product detail
Clinical Data

The Evidence

15-18%
CT-verified visceral fat reduction at 26 weeks in Phase III trials
800+
Patients enrolled across two Phase III pivotal trials
Cognition
Improved verbal memory and executive function in adults over 60
Baker et al., Archives of Neurology, 2012

Tesamorelin (brand name Egrifta) received FDA approval in November 2010 for reduction of excess abdominal fat in HIV-associated lipodystrophy.

What Changes

This Changes Your Body Without Changing Your Weight

Tesamorelin targets visceral fat through pulsatile growth hormone release. The result is measurable reduction in the fat that surrounds your organs, improved metabolic markers, and a leaner waistline, without the scale moving significantly.

Cinematic editorial
Comparison

Sermorelin (GHRH 1-29) vs. Tesamorelin (Modified GHRH 1-44)

Sermorelin (GHRH 1-29)Tesamorelin (Modified GHRH 1-44)
29-amino acid truncated GHRH analog 44-amino acid full-length GHRH analog with N-terminal stabilization
Short half-life (10-20 minutes), requires daily bedtime dosing Enhanced stability from trans-3-hexonoic acid modification
General GH restoration for sleep, recovery, body composition FDA-approved specifically for visceral fat reduction
No Phase III clinical trial data for visceral fat reduction Two Phase III trials with CT-verified results in 800+ patients
Broad GH axis support without compartment-specific targeting Selective visceral adipose tissue targeting documented on imaging
Available through compounding pharmacies Available through compounding pharmacies for off-label use
Comparison

GLP-1 RECEPTOR AGONISTS VS. TESAMORELIN

GLP-1 RECEPTOR AGONISTS VS. TESAMORELINGLP-1 RECEPTOR AGONISTS VS. TESAMORELIN
Targets total body weight through appetite suppression Targets visceral fat through pulsatile growth hormone release
Reduces subcutaneous and visceral fat indiscriminately Selective reduction of organ-surrounding adipose tissue on CT imaging
Scale-dependent results. Weight loss is the metric. Composition-dependent results. Waist circumference is the metric.
Muscle mass loss reported in 20-40% of patients Weight-neutral by design. Preserves lean mass.
Requires ongoing use to maintain appetite suppression Works through the body's endogenous growth hormone axis
Systemic mechanism affecting hunger, satiety, gastric emptying Compartment-specific mechanism targeting visceral fat stores
Product Information

Details

Tesamorelin is a lab-built peptide made of 44 amino acids, modeled after a hormone your body already produces: growth hormone-releasing hormone (GHRH). It's been chemically stabilized so your body doesn't break it down before it can do its job.
FDA-approved in 2010 under the brand name Egrifta, tesamorelin is the first and only medication specifically approved to reduce excess visceral fat, the deep, hidden fat packed around your organs.
Here's how it works: tesamorelin signals your pituitary gland (a small structure at the base of your brain) to release growth hormone the way it naturally would, in controlled pulses, not a constant flood. Your body's own feedback system stays intact. You're not overriding anything. You're restoring a signal.
What separates tesamorelin from other peptides is the clinical proof. Two large-scale Phase III trials enrolled over 800 patients and showed statistically significant reductions in visceral fat, confirmed by CT imaging, not just a scale.
One thing worth understanding: tesamorelin is weight-neutral by design. It does not reduce body weight, because the problem it solves is not weight. It's where the fat lives. You may weigh the same and be meaningfully healthier.
Visceral fat is metabolically active tissue that secretes inflammatory cytokines, disrupts insulin signaling, and independently predicts cardiovascular events. Tesamorelin targets this compartment with selectivity that diet and exercise alone struggle to achieve.
Emerging research shows cognitive benefits. A 2015 study demonstrated improved verbal memory and executive function in adults over 60. Separately, tesamorelin reduces hepatic fat accumulation, improving liver function markers in patients with non-alcoholic fatty liver profiles.
Administer via subcutaneous injection using a syringe. Inject into the abdomen, rotating sites. Administer at approximately the same time daily.
Your prescribing provider will determine cycle length based on clinical goals and imaging data. Store refrigerated at 36 to 46 degrees Fahrenheit. Protect from light.
The most common side effects are injection site reactions (redness, itching, swelling) reported in approximately 8-12% of patients. Joint pain and peripheral edema may occur, consistent with GH elevation. Paresthesia (tingling) has been reported. Tesamorelin is contraindicated in pregnancy and in patients with active malignancy due to its GH-stimulating mechanism.
Disclaimer and Transparency

Important Information About Compounded Injectables

  • Compounded medications are not reviewed or approved by the FDA and do not undergo the same pre-market evaluation as FDA-approved drugs.
  • IVUSE peptide injections are prepared using peptide ingredients by FDA-registered, U.S.-licensed 503A & 503B compounding pharmacies, where available and clinically appropriate.
  • Availability and formulation may vary based on state regulations, evolving clinical guidance, and pharmacy partners.

All prescriptions, treatment decisions, and care plans are made independently by licensed healthcare providers using their professional judgment. Images and product depictions are for illustration only; actual packaging and supplies may vary.

*If you are interested in a prescription product, IVUSE will coordinate a telehealth visit with a licensed medical provider who will determine whether you are an appropriate candidate based on your health profile and current standards of care. If approved, a prescription will be issued and filled by one of our partner pharmacies. All prescriptions are subject to provider discretion and clinical appropriateness.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. All information provided here is for educational purposes only and does not replace personalized medical advice from a qualified healthcare professional.

Stop the medication and contact your provider if you experience persistent or concerning symptoms. Seek immediate medical care if you develop signs of a severe allergic reaction (such as hives, facial swelling, or difficulty breathing) or any rapidly worsening symptom.

Questions

Tesamorelin FAQ

Is Tesamorelin the same as HGH?
No. Tesamorelin is a growth hormone-releasing hormone analog. It stimulates your pituitary gland to produce its own growth hormone in a natural, pulsatile pattern. Exogenous HGH bypasses the pituitary entirely and delivers synthetic growth hormone directly, which can suppress your body's own production. Tesamorelin works with your biology. HGH replaces it.
Can I take this with my GLP-1?
Yes. Tesamorelin and GLP-1 agonists target different biological systems. GLP-1 manages appetite and drives overall weight loss. Tesamorelin targets the growth hormone axis to mobilize visceral fat specifically. Many IVUSE+ patients use both as part of a combined protocol. Your prescribing clinician will evaluate your full medication profile during intake.
Will I lose weight on the scale?
Likely not. Tesamorelin's effect is weight-neutral per the FDA label. It reduces visceral fat while preserving lean mass. The scale may stay the same or even increase slightly as body composition shifts. The changes show in measurements, photos, and how your clothes fit.
How fast does Tesamorelin work?
Clinical trials measured outcomes at 26 weeks (about 6 months). Some patients report subjective changes in body composition, sleep quality, and energy within the first 4-8 weeks. Measurable visceral fat reduction on imaging typically requires 3-6 months of consistent daily use.
What are the side effects?
The most common side effect is injection site reactions (redness, swelling, or itching), occurring in about 8-12% of patients. Other reported effects include joint pain, peripheral edema (mild swelling), and paresthesia (tingling). These are generally mild and transient. Tesamorelin is contraindicated during pregnancy and in patients with active malignancy.
Is this FDA-approved?
Tesamorelin was FDA-approved in November 2010 under the brand name Egrifta for reduction of excess abdominal fat in HIV-associated lipodystrophy. IVUSE+ clinicians prescribe compounded Tesamorelin off-label for non-HIV patients after individual medical evaluation. Off-label prescribing is a standard, legal medical practice when a clinician determines it is appropriate for a patient.
What happens after I order?
After placing your order, you'll receive a clinical intake questionnaire. A board-certified clinician reviews your health history, current medications, and treatment goals. If approved, your prescription is sent to a licensed U.S. compounding pharmacy and shipped to your door within 2-4 business days. If you're not a candidate, you'll be notified and refunded in full.
How should I store and administer?
Store refrigerated at 2-8°C (36-46°F). Protect from light. Do not freeze. Administer via subcutaneous injection in the abdomen using a 27-31 gauge needle. Rotate injection sites. Inject at the same time each day, ideally in the morning or before bed.
Do I need baseline labs?
Your clinician may recommend baseline labs including IGF-1, fasting glucose, and HbA1c. These help establish your starting point and allow monitoring of your response to treatment. Lab requirements vary by patient and are determined during your clinical intake.
How long should I stay on protocol?
Clinical trial data covers 26-52 weeks of use. Your prescribing clinician will recommend a duration based on your individual response, goals, and lab results. Some patients use Tesamorelin in defined cycles. Others maintain it as part of an ongoing optimization protocol.
After You Order

What happens next

01

Choose Your Protocol

No consultation fee. No hidden costs. Single vials or a full 12-week cycle.

02

Complete Your Clinical Intake

A board-certified clinician reviews your health history, medications, and goals. Asynchronous. No appointments. No waiting rooms.

03

Your Prescription Ships

Compounded by a licensed U.S. pharmacy. Delivered to your door in 2-4 business days. Cold-shipped when required.

Clinical Recommendation

Stack Your Protocol

NAD+
Peptide Therapy

NAD+

NAD+ fuels the repair and energy systems inside every cell. When levels are optimized, your cells recover faster, produce energy more efficiently, and age more slowly at a molecular level. Tesamorelin builds on that foundation with a specific, clinically proven job: reducing the deep organ fat that drives metabolic dysfunction. One restores the engine. The other removes the drag.

Starting at $141.00
GHK-CU
Peptide Therapy

GHK-CU

GHK-Cu is a repair signal. It tells your body to rebuild, remodel, and restore tissue from the inside out. Tesamorelin adds a targeted layer on top of that: clinically proven visceral fat reduction. One rebuilds the infrastructure. The other clears out what's weighing it down.

Starting at $118.00
MOTS-C
Peptide Therapy

MOTS-C

MOTS-c works at the cellular level, flipping on your body's energy efficiency switch (a pathway called AMPK) so your cells burn fuel more effectively. Tesamorelin works at the hormonal level, telling your body to mobilize and reduce the deep fat packed around your organs. One optimizes how your cells use energy. The other redirects where your body stores it.

Starting at $90.00

You've spent years working on the fat that would cooperate. This is for the fat that wouldn't.

Tesamorelin is a prescription peptide that targets visceral fat through your body's natural growth hormone system. FDA-approved. Clinician-prescribed. Delivered to your door in 2 to 4 business days.

Tesamorelin is a prescription medication. Off-label prescribing is standard medical practice. Your order initiates a clinical intake. A board-certified clinician reviews your health history before your prescription ships. If you are pregnant, breastfeeding, or have active malignancy, tesamorelin is contraindicated.

Tesamorelin $600.00